Patents by Inventor Wilfried Hornberger

Wilfried Hornberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210147381
    Abstract: The invention relates to 1,2,3,4-substituted quinoline compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Application
    Filed: July 16, 2018
    Publication date: May 20, 2021
    Inventors: Wilhelm AMBERG, Hervé GENESTE, Wilfried HORNBERGER, Udo LANGE, Mario MEZLER, Michael OCHSE, Frank OELLIEN, Sean C. TURNER, Jeroen VAN BERGEIJK, Elizabeth VAN DER KAM
  • Publication number: 20200055817
    Abstract: The invention relates to heterocyclic compounds of formula (I) as SIP modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment or alleviation of diseases or disorders mediated by an SIP receptor.
    Type: Application
    Filed: November 2, 2017
    Publication date: February 20, 2020
    Inventors: Wilhelm AMBERG, Jeroen VAN BERGEIJK, Herve GENESTE, Wilfried HORNBERGER, Elizabeth Louise VAN DER KAM, Udo LANGE, Mario MEZLER, Michael OCHSE, Frank OELLIEN, Patrick WALLESER, Sean C. TURNER
  • Patent number: 10556907
    Abstract: The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: February 11, 2020
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Udo Lange, Michael Ochse, Elizabeth van der Kam, Jeroen van Bergeijk, Sean Turner, Frank Oellien, Patrick Walleser, Wilhelm Amberg, Wilfried Hornberger, Herve Geneste, Mario Mezler, Charles Hutchins
  • Patent number: 10100048
    Abstract: The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: October 16, 2018
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Sean Colm Turner, Margaretha Henrica Maria Bakker, Marcel van Gaalen, Falko Ernst Wolter, Wilfried Hornberger, Marjoleen Nijsen
  • Patent number: 9862704
    Abstract: The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for the treatment of vasopressin-related disorders.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 9, 2018
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Hervé Geneste, Wilfried Hornberger, Charles W. Hutchins, Katja Jantos, Andreas Kling, Loic Laplanche, Marcel Van Gaalen
  • Patent number: 9840495
    Abstract: The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for treatment of vasopressin-related disorders.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 12, 2017
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Hervé Geneste, Wilfried Hornberger, Charles W. Hutchins, Katja Jantos, Andreas Kling, Loic Laplanche, Marcel Van Gaalen
  • Patent number: 9688678
    Abstract: The present invention relates to novel substituted oxindole derivatives of the formula I wherein A is a ring selected from phenyl and 6-membered hetaryl containing 1 or 2 nitrogen atoms as ring members, where ring A carries one substituent R6 and optionally one substituent R7; B is a ring selected from phenyl and a monocyclic or bicyclic heteroaromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S as ring members, where ring B may carry 1, 2 or 3 substituents R8; X1, X2, X3 and X4, independently of each other, are selected from —CH2—, —O—, —S(O)c—, —NH—, —C(O)—, —CH2CH2—, —CH2O—, —OCH2—, —S(O)cCH2—, —CH2S(O)c—, CH2NH—, —NHCH2—, —CH2C(O)— and C(O)CH2—; X5 is NH, CH2 or O; and wherein c, R1, R2, (R3)a, (R4)b, R5, R6, R7, and R8 are as defined in the claims. The present invention also relates to pharmaceutical compositions comprising the novel substituted oxindole derivatives of the formula I, and to their use for the treatment of vasopressin-related disorders.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: June 27, 2017
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Hervé Geneste, Wilfried Hornberger, Katja Jantos, Andreas Kling, Marcel Van Gaalen
  • Patent number: 9657002
    Abstract: The present invention relates to novel substituted oxindole derivatives of formula (I), pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 23, 2017
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Katja Jantos, Wilfred Braje, Herve Geneste, Andreas Kling, Liliane Unger, Berthold Behl, Marcel van Gaalen, Wilfried Hornberger, Loic Laplanche, Silke Weber
  • Patent number: 9617226
    Abstract: The present invention relates to novel fused heterocyclic or carbocyclic compounds of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising these compounds, and to their use for the treatment of vasopressin-related disorders.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: April 11, 2017
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Wilfried Braje, Jayne Froggett, Hervé Geneste, Wilfried Hornberger, Katja Jantos, Andreas Kling, Marcel van Gaalen
  • Publication number: 20170057966
    Abstract: The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Application
    Filed: August 26, 2016
    Publication date: March 2, 2017
    Inventors: Udo Lange, Michael Ochse, Elizabeth van der Kam, Jeroen van Bergeijk, Sean Turner, Frank Oellien, Patrick Walleser, Wilhelm Amberg, Wilfried Hornberger, Herve Geneste, Mario Mezler, Charles Hutchins
  • Publication number: 20170050959
    Abstract: The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R3, R4, R5, R6 and R7 are defined according to claim 1, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivaties can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.
    Type: Application
    Filed: November 7, 2016
    Publication date: February 23, 2017
    Inventors: Wilfried Lubisch, Wilfried Hornberger, Thorsten K. Oost, Daryl Richard Sauer, Liliane Unger, Wolfgang Wernet, Hervé Geneste
  • Patent number: 9567325
    Abstract: The present invention relates to novel carboxamide compounds and their use as a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity and to a method for the therapeutic and/or prophylactic treatment by administering an effective amount of at least one of these carboxamide compounds. The carboxamide compounds are compounds of the general formula I in which W—R2 is selected from and R1, R2, R3a, R3b, Y1, Y2, Y3, Y4, X, Q, m, k, Rw and Rw* have the meanings mentioned in the claims, the tautomers thereof and the pharmaceutically suitable salts thereof.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: February 14, 2017
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Andreas Kling, Helmut Mack, Katja Jantos, Achim Moeller, Wilfried Hornberger, Charles W. Hutchins
  • Publication number: 20170008875
    Abstract: The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for treatment of vasopressin-related disorders.
    Type: Application
    Filed: December 19, 2014
    Publication date: January 12, 2017
    Inventors: Hervé GENESTE, Wilfried HORNBERGER, Charles W. HUTCHINS, Katja JANTOS, Andreas KLING, Loic LAPLANCHE, Marcel VAN GAALEN
  • Patent number: 9540370
    Abstract: The present invention relates to novel heterocyclic compounds of formula I wherein the variables are as defined in the claims or the description, which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), compositions containing the compounds, their use for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a compound that modulates, preferably inhibits, the activity of glycogen synthase kinase 3?, and methods of treatment of medical disorders susceptible to treatment with a compound that modulates glycogen synthase kinase 3? activity using the compounds.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: January 10, 2017
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO., KG.
    Inventors: Sean Colm Turner, Helmut Mack, Margaretha Henrica Maria Bakker, Marcel van Gaalen, Carolin Hoft, Wilfried Hornberger
  • Publication number: 20170001982
    Abstract: The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for the treatment of vasopressin-related disorders.
    Type: Application
    Filed: December 19, 2014
    Publication date: January 5, 2017
    Inventors: Hervé GENESTE, Wilfried HORNBERGER, Charles W. HUTCHINS, Katja JANTOS, Andreas KLING, Loic LAPLANCHE, Marcel VAN GAALEN
  • Patent number: 9527811
    Abstract: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula I in which R1, R2, R3a, R3b, R4, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: December 27, 2016
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Helmut Mack, Andreas Kling, Katja Jantos, Achim Moeller, Wilfried Hornberger, Charles W. Hutchins
  • Patent number: 9527856
    Abstract: The present invention relates to novel substituted oxindole derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising compounds I and their use for the treatment of vasopressin-related disorders.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 27, 2016
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Wilfried Braje, Hervé Geneste, Wilfried Hornberger, Katja Jantos, Andreas Kling, Claudia Krack, Marcel Van Gaalen
  • Publication number: 20160362394
    Abstract: The present invention relates to novel carbamate-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.
    Type: Application
    Filed: August 23, 2016
    Publication date: December 15, 2016
    Inventors: Astrid Netz, Thorsten Oost, Hervé Geneste, Wilfried Braje, Wolfgang Wernet, Liliane Unger, Wilfried Hornberger, Wilfried Lubisch
  • Patent number: 9487505
    Abstract: The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R3, R4, R5, R6 and R7 are defined according to claim 1, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivatives can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: November 8, 2016
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Wilfried Lubisch, Wilfried Hornberger, Thorsten K. Oost, Daryl Richard Sauer, Liliane Unger, Wolfgang Wernet, Hervé Geneste
  • Patent number: 9434713
    Abstract: The present invention relates to novel 5,6-disubstituted oxindole derivatives and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising such derivatives, and to the use of such derivatives for the manufacture of a medicament, and methods of treating disorders in a subject in need thereof, such as vasopressin-dependent disorders, using 5,6-disubstituted oxindole derivatives.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: September 6, 2016
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Wilfried Braje, Thorsten Oost, Astrid Netz, Wolfgang Wernet, Liliane Unger, Wilfried Hornberger, Wilfried Lubisch